小分子肿瘤免疫治疗药物的临床研究进展

Progress in clinical research of small molecule tumor immunotherapy drugs

以抗细胞毒性T淋巴细胞相关抗原4(CTLA-4)和程序性死亡受体1(PD-1)单抗类药物为代表的免疫检查点抑制剂在肿瘤免疫治疗领域取得了突破性进展。小分子肿瘤免疫治疗药物一般通过调节肿瘤免疫抑制微环境或靶向先天/适应性免疫途径,产生抗肿瘤作用。小分子肿瘤免疫治疗药物可以弥补单抗类药物的不足,补充现有的治疗方式,与单抗类药物联用可产生协同效应,具有巨大的应用潜力。

Immuno-oncology represented by CTLA-4 and PD-1 monoclonal antibody has made breakthroughs in the field of cancer therapy.Small molecule tumor immunotherapy drugs generally produce antitumor effects by modulating the tumor immunosuppressive microenvironment or targeting the innate/adaptive immune pathway.Small molecule tumor immunotherapy drugs can make up for the deficiency of monoclonal antibody and supplement existing treatments,and combined with monoclonal antibody can produce potentially synergistic effects with great application potential.